Aligos Therapeutics (NASDAQ:ALGS) Shares Gap Up to $10.18

Aligos Therapeutics, Inc. (NASDAQ:ALGS) gapped up prior to trading on Friday . The stock had previously closed at $10.18, but opened at $10.60. Aligos Therapeutics shares last traded at $10.21, with a volume of 35,827 shares.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and issued a $75.00 price target on shares of Aligos Therapeutics in a research note on Friday.

Aligos Therapeutics Trading Down 3.0 %

The company has a 50 day simple moving average of $13.26 and a 200 day simple moving average of $16.41. The stock has a market cap of $770.95 million, a P/E ratio of -7.95 and a beta of 2.18.

Aligos Therapeutics (NASDAQ:ALGS) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($4.00) by $4.75. The company had revenue of $1.06 million for the quarter. Aligos Therapeutics had a negative net margin of 1,100.48% and a negative return on equity of 110.59%. During the same quarter last year, the business earned ($10.75) earnings per share. As a group, sell-side analysts expect that Aligos Therapeutics, Inc. will post -8.15 earnings per share for the current year.

Hedge Funds Weigh In On Aligos Therapeutics

Large investors have recently modified their holdings of the business. Armistice Capital LLC raised its stake in shares of Aligos Therapeutics by 5.3% during the 2nd quarter. Armistice Capital LLC now owns 7,256,410 shares of the company’s stock worth $2,540,000 after purchasing an additional 363,000 shares in the last quarter. Acadian Asset Management LLC raised its position in Aligos Therapeutics by 26.1% during the second quarter. Acadian Asset Management LLC now owns 829,485 shares of the company’s stock worth $289,000 after acquiring an additional 171,490 shares in the last quarter. Opaleye Management Inc. grew its position in shares of Aligos Therapeutics by 25.7% in the 1st quarter. Opaleye Management Inc. now owns 1,630,000 shares of the company’s stock valued at $1,597,000 after acquiring an additional 333,000 shares during the period. Finally, Altitude Crest Partners Inc. bought a new position in shares of Aligos Therapeutics in the 4th quarter valued at about $1,889,000. 60.43% of the stock is currently owned by institutional investors and hedge funds.

About Aligos Therapeutics

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).